Skip to content
OpenCapital
Get started

TuHURA Biosciences, Inc. HURA Debt Repayments

Debt Repayments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$500M—
CTO
Citius Oncology, Inc.CTOR
$20M-60.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$868K—

Other financials

Income statement

See full
Revenue-—
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%—
Debt / equity0×0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt.

The official record: TuHURA Biosciences, Inc.’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s debt repayments?
TuHURA Biosciences, Inc. (HURA) reported debt repayments of $0 in Q4 2024.
How has TuHURA Biosciences, Inc.'s debt repayments changed year-over-year?
TuHURA Biosciences, Inc.'s debt repayments decreased by 100.0% year-over-year, from $671.25K to $0.
What does debt repayments mean?
Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.